ADILW - ADMAバイオロジックス (Adial Pharmaceuticals Inc)

ADILWのニュース

   Adial Pharmaceuticals Inc. (NASDAQ:ADIL) Is Currently -213.58% Below Its 52-Week High, But Upside Potential Is Still There.  2022/04/09 13:00:00 Marketing Sentinel
In last trading session, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) saw 0.52 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $1.62 trading at -$0.2 or -10.99% at ring of the bell on the day assigns it a market valuation of $38.07M. That closing price of ADIL’s stock is … Adial Pharmaceuticals Inc. (NASDAQ:ADIL) Is Currently -213.58% Below Its 52-Week High, But Upside Potential Is Still There. Read More »
   Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th  2022/03/22 13:15:00 GlobeNewswire
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Adial’s Chief Executive Officer will participate in a fireside chat at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Those who wish to attend the conference must first sign up to become an M-Vest member.
   Adial Pharmaceuticals announces $10M registered direct offering  2022/02/11 14:07:01 Seeking Alpha
Adial Pharmaceuticals (ADIL) will sell 4.2M shares to a single institutional investor worth ~$10M in a registered direct offering and issue warrants in a concurrent private…
   Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate''s PNV-5032 as a Potential Treatment for Asthma  2022/02/09 14:25:00 Benzinga
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company") , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model. PNV-5032 Relevant Information Greater than 1000-fold selective over the adenosine A1 receptor in potency assays Demonstrated solubility more than 100 times greater than other selective adenosine compounds of the same class currently known to the Company Solubility of an inhaled product allows dissolution in the aerosolized mist for fine distribution over the bronchioles and can be important in facilitating bronchiole membrane penetration Findings indicate drug development potential of molecules of this class, possibly to treat asthma Covered by a composition of matter patent application for patent protection through 2042 with expected statutory extension to 2047 Study Design Sheep, which respond to allergens and adenosine challenges in a manner similar to humans, were initially challenged with an aerosolized dose of Ascaris Sum allergens.
   Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovates PNV-5032 as a Potential Treatment for Asthma  2022/02/09 14:25:00 GlobeNewswire
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company) , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.
   -$0.21 Earnings Per Share Expected for Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) This Quarter  2021/12/04 19:26:43 Dakota Financial News
Analysts expect that Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) will post earnings per share (EPS) of ($0.21) for the current quarter, according to Zacks. Zero analysts have provided estimates for Adial Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.21). Adial Pharmaceuticals reported earnings of ($0.24) per []
   Green - Geode Capital Management LLC Buys 10,261 Shares of Adial Pharmaceuticals, Inc  2021/11/30 09:13:07 Business Mag
Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the
   Geode Capital Management LLC Buys 10,261 Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)  2021/11/30 09:10:44 ETF Daily News
Geode Capital Management LLC raised its stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,246 shares of the companys stock after acquiring an additional 10,261 shares during the quarter. Geode Capital Management [] The post Geode Capital Management LLC Buys 10,261 Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) appeared first on ETF Daily News .
   Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer  2021/11/29 14:00:00 Intrado Digital Media
PNV2 demonstrates reduction of metastases in animal model PNV2 demonstrates reduction of metastases in animal model
   REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments  2021/11/17 14:42:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments.
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Wallstreet:Online
ONWARD trial enrollment closed; trial completion expected in Q1 2022 CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Intrado Digital Media
ONWARD trial enrollment closed; trial completion expected in Q1 2022 ONWARD trial enrollment closed; trial completion expected in Q1 2022
   Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder  2021/08/20 14:45:00 Intrado Digital Media
On track for trial completion in the first quarter of 2022
   Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments  2021/08/20 13:40:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, will host a conference call at 11:00 A.M. Eastern Time today, August 20, 2021 to provide a clinical update and discuss the latest business developments.
   Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments  2021/08/12 18:50:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments.

calendar